NOTV — Inotiv, Inc.

Inotiv (NOTV) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $138.1 million, up 5.9% year-over-year from $130.4 million in Q4 2024.
• Fiscal Year 2025 Revenue: $513 million, a 4.5% increase from $490.7 million in FY 2024.
• DSA Revenue: $51.6 million in Q4 2025, a 15.7% increase year-over-year; FY 2025 DSA revenue totaled $187.9 million, up 4.3%.
• RMS Revenue: $86.5 million in Q4 2025, a slight increase of 0.8% year-over-year; FY 2025 RMS revenue was $325.1 million, up 4.7%.
• Net Loss: $8.6 million in Q4 2025 ($0.25 loss per diluted share), improved from a net loss of $18.9 million in Q4 2024. Total net loss for FY 2025 was $68.6 million ($2.11 loss per diluted share).
• Adjusted EBITDA: $11.8 million in Q4 2025 (8.5% of total revenue), up from $5.4 million (4.1%) in Q4 2024. FY 2025 adjusted EBITDA was $34 million (6.6% of total revenue), compared to $18.2 million (3.7%) in FY 2024.
• Cash Flow: Generated $14.3 million in cash from operations in Q4 2025, with a cash balance of $21.7 million.

2. Strategic Updates and Business Highlights

• Demand Growth: Strong demand in the Discovery & Safety Assessment (DSA) segment, with a 61% increase in net DSA awards in Q4 2025.
• Site Consolidation: Continued efforts in RMS site consolidation, with one facility closed in October 2025, aiming for annual savings of $6 million to $7 million.
• Cybersecurity Incident: Acknowledged a cybersecurity incident that disrupted operations; however, the company maintained momentum and continued to execute on product and service delivery.
• CRM Integration: Transitioned to a new CRM system to enhance operational efficiencies and improve customer communication.

3. Forward Guidance and Outlook

• No Formal Guidance: Inotiv is not providing formal guidance for FY 2026 due to uncertainties in market conditions and client demand.
• Positive Trends: Management noted encouraging trends in DSA quoting and awards, with expectations for continued revenue growth based on recent performance.

4. Bad News, Challenges, or Points of Concern

• Cybersecurity Impact: The cybersecurity incident posed significant operational challenges and may have affected earnings and client confidence, though the full impact remains difficult to quantify.
• Market Conditions: Ongoing geopolitical and macroeconomic uncertainties could pose risks to future performance.
• RMS Margin Pressure: Margins in the RMS segment were impacted by increased costs associated with animal models and services, despite overall improvements in operational efficiency.

5. Notable Q&A Insights

• Lead Times: DSA studies can typically start within weeks, while larger animal safety assessments may take 3-9 months.
• Customer Budgets: Early indications suggest a positive outlook for customer budgets in FY 2026, with increased quoting activity.
• Monoclonal Antibodies: Minimal revenue exposure to monoclonal antibodies, indicating limited impact from FDA guidance on large animal models.
• Operational Efficiency: Continued focus on reducing fixed costs and improving margins through site consolidation and operational enhancements.

Overall, Inotiv's Q4 2025 results reflect a positive trajectory in revenue growth and operational improvements, despite challenges from a cybersecurity incident and ongoing market uncertainties. The company remains focused on strategic initiatives to enhance efficiency and client service while navigating potential headwinds.